Isomorphic Labs raises $5 billion to advance AI-designed medicines

Isomorphic Labs announced a $5 billion Series C funding round on November 17 to expand its AI drug-design technology and advance potential medicines toward clinical trials. Greenoaks and Sequoia Capital co-led the financing, according to the company's announcement.
Andreessen Horowitz joined the round alongside other new investors. Alphabet invested again, and existing backers including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated.
The London-headquartered company plans to develop its Isomorphic Labs Drug Design Engine, or IsoDDE, further. The system combines AI simulation models intended to work across different therapeutic areas and drug types. Isomorphic says its internal oncology and immunology programs, alongside partnered work, have produced positive preclinical results. Those are company-reported findings, not evidence that a treatment has succeeded in human trials.
The funding will also support biological models, drug candidates and infrastructure for translational and clinical development. Isomorphic's own summary describes scaling both its engine and therapeutic pipeline. The significance is the next step: supporting the transition from AI-designed candidates and preclinical work toward testing potential medicines in people.
Sources and citations
Revision history
Published .